G. Pillai, F. Mentré, and J. Steimer, Non-Linear Mixed Effects Modeling ??? From Methodology and Software Development to Driving Implementation in Drug Development Science, Journal of Pharmacokinetics and Pharmacodynamics, vol.72, issue.6, pp.161-83, 2005.
DOI : 10.1007/s10928-005-0062-y

S. Beal, L. Sheiner, A. Boeckmann, and R. Bauer, NONMEM User's guides, Icon development Solutions, 1989.

M. Al-banna and A. Kelman, Experimental design and efficient parameter estimation in population pharmacokinetics, Journal of Pharmacokinetics and Biopharmaceutics, vol.46, issue.4, pp.347-60, 1990.
DOI : 10.1007/BF01062273

N. Holford, H. Kimko, J. Monteleone, and C. Peck, Simulation of Clinical Trials, Annual Review of Pharmacology and Toxicology, vol.40, issue.1, pp.209-243, 2000.
DOI : 10.1146/annurev.pharmtox.40.1.209

A. Atkinson and A. Donev, Optimum Experimental Design, 1992.
DOI : 10.1007/978-3-642-04898-2_434

R. Fisher, The Logic of Inductive Inference, Journal of the Royal Statistical Society, vol.98, issue.1, pp.39-54, 1935.
DOI : 10.2307/2342435

F. Mentré, A. Mallet, and D. Baccar, Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-471, 1997.
DOI : 10.1093/biomet/84.2.429

S. Retout, F. Mentré, and R. Bruno, Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics, Statistics in Medicine, vol.26, issue.6, pp.2623-2662, 2002.
DOI : 10.1002/sim.1041

C. Bazzoli, S. Retout, and F. Mentré, Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0, Computer Methods and Programs in Biomedicine, vol.98, issue.1, pp.55-65, 2010.
DOI : 10.1016/j.cmpb.2009.09.012

URL : https://hal.archives-ouvertes.fr/inserm-00431457

J. Nyberg, S. Ueckert, E. Strömberg, S. Hennig, M. Karlsson et al., PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool, Computer Methods and Programs in Biomedicine, vol.108, issue.2, pp.789-805, 2012.
DOI : 10.1016/j.cmpb.2012.05.005

I. Gueorguieva, K. Ogungbenro, G. Graham, S. Glatt, L. Aarons et al., A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies, Comput Methods Prog Biomed. Pharm Res, vol.8629, issue.16, pp.51-61, 2007.

L. Foo and S. Duffull, Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics, Journal of Biopharmaceutical Statistics, vol.253, issue.4, pp.886-902, 2010.
DOI : 10.1080/10543400600851880

S. Retout and F. Mentré, Optimization of Individual and Population Designs Using Splus, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.417-460, 2003.
DOI : 10.1023/B:JOPA.0000013000.59346.9a

Y. Merlé and F. Mentré, Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.1, pp.101-126, 1995.
DOI : 10.1007/BF02353788

L. Sheiner, S. Beal, B. Rosenberg, and V. Marathe, Forecasting individual pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.26, issue.3, pp.294-305, 1979.
DOI : 10.1002/cpt1979263294

L. Sheiner and S. Beal, Bayesian Individualization of Pharmacokinetics: Simple Implementation and Comparison with Non-Bayesian Methods, Journal of Pharmaceutical Sciences, vol.71, issue.12, pp.1344-1352, 1982.
DOI : 10.1002/jps.2600711209

F. Fedorov, Mixed models: design of experiments. Presented at Design and analysis of experiments, 2011.

R. Savic and M. Karlsson, Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, The AAPS Journal, vol.11, issue.3, pp.558-69, 2009.
DOI : 10.1208/s12248-009-9133-0

F. Mentré, P. Burtin, Y. Merlé, J. Van-bree, A. Mallet et al., Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics, Therapeutic Innovation & Regulatory Science, vol.29, issue.3, pp.997-1019, 1995.
DOI : 10.1177/009286159502900321

N. Frey, S. Grange, and T. Woodworth, Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis, The Journal of Clinical Pharmacology, vol.47, issue.suppl II, pp.754-66, 2010.
DOI : 10.1177/0091270009350623

G. Verbeke and G. Molenberghs, Linear Mixed Models for Longitudinal Data, 2000.
DOI : 10.1007/978-1-4612-2294-1_3

J. Pilz, Bayesian estimation and experimental design in linear regression models. Leipzig: Teubner-Texte, 1983.

A. Boeckmann, L. Sheiner, and S. Beal, NONMEM users guide ? Part V introductory guide. Ellicott City: Icon development Solutions, 2011.

J. Mcgree, J. Eccleston, and S. Duffull, Compound Optimal Design Criteria for Nonlinear Models, Journal of Biopharmaceutical Statistics, vol.48, issue.2, pp.646-61, 2008.
DOI : 10.1080/10543400802071352

B. Jones and J. Wang, Constructing optimal designs for fitting pharmacokinetic models, Statistics and Computing, vol.9, issue.3, pp.209-227, 1999.
DOI : 10.1023/A:1008922030873

B. Jones, J. Wang, P. Jarvis, and W. Byrom, Design of cross-over trials for pharmacokinetic studies, Journal of Statistical Planning and Inference, vol.78, issue.1-2, pp.307-323, 1999.
DOI : 10.1016/S0378-3758(98)00221-3